Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 8Phase NA 2Phase 3 2Phase 4 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 61Prostatic Neoplasms 43Lung Neoplasms 35Multiple Myeloma 34Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 22Colorectal Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Neoplasm Metastasis 19Ovarian Neoplasms 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Leukemia, Myeloid, Acute 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Nasopharyngeal Carcinoma 11Myasthenia Gravis 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Melanoma 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7

Interventions

asciminib 2nilotinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 30 days × Clear all
NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Sir Mortimer B. Davis - Jewish General Hospital

Phase 3 Terminated
8 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡